Monte Rosa(GLUE.US) Enters Into License Agreement For Molecular Glue Degrader With Novartis(NVS.US)
Market IntelMonday, Oct 28, 2024 9:30 am ET
1min readMonte Rosa Therapeutics (GLUE.US) has entered into an exclusive license agreement with Novartis (NVS.US) to advance its VAV1-directed molecular glue degraders (MGD), including MRT-6160, for autoimmune diseases. Monte Rosa's shares jumped nearly 50% before the US market opened on Monday on news of the deal.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet